Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q1169059> ?p ?o }
Showing triples 1 to 56 of
56
with 100 triples per page.
- Q1169059 subject Q7145095.
- Q1169059 subject Q7482068.
- Q1169059 subject Q8275351.
- Q1169059 subject Q8297683.
- Q1169059 subject Q8808791.
- Q1169059 subject Q8965786.
- Q1169059 abstract "Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed. There was some interest in its use in the treatment of treatment-resistant schizophrenia.".
- Q1169059 atcPrefix "N05".
- Q1169059 atcSuffix "AL04".
- Q1169059 bioavailability "96.0".
- Q1169059 casNumber "117591-79-4".
- Q1169059 drugbank "DB00409".
- Q1169059 fdaUniiCode "0223RD59PE".
- Q1169059 iupacName "3-bromo-N-(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide".
- Q1169059 pubchem "54477".
- Q1169059 thumbnail Remoxipride.svg?width=300.
- Q1169059 wikiPageExternalLink CH121.html.
- Q1169059 wikiPageWikiLink Q15335165.
- Q1169059 wikiPageWikiLink Q18022891.
- Q1169059 wikiPageWikiLink Q185935.
- Q1169059 wikiPageWikiLink Q2554162.
- Q1169059 wikiPageWikiLink Q274160.
- Q1169059 wikiPageWikiLink Q410943.
- Q1169059 wikiPageWikiLink Q41112.
- Q1169059 wikiPageWikiLink Q417731.
- Q1169059 wikiPageWikiLink Q46.
- Q1169059 wikiPageWikiLink Q4914025.
- Q1169059 wikiPageWikiLink Q7145095.
- Q1169059 wikiPageWikiLink Q731938.
- Q1169059 wikiPageWikiLink Q7482068.
- Q1169059 wikiPageWikiLink Q7512419.
- Q1169059 wikiPageWikiLink Q758295.
- Q1169059 wikiPageWikiLink Q8275351.
- Q1169059 wikiPageWikiLink Q8297683.
- Q1169059 wikiPageWikiLink Q846316.
- Q1169059 wikiPageWikiLink Q8808791.
- Q1169059 wikiPageWikiLink Q8965786.
- Q1169059 wikiPageWikiLink Q899107.
- Q1169059 wikiPageWikiLink Q9368.
- Q1169059 wikiPageWikiLink Q9377.
- Q1169059 atcPrefix "N05".
- Q1169059 atcSuffix "AL04".
- Q1169059 bioavailability "96.0".
- Q1169059 casNumber "117591".
- Q1169059 drugbank "DB00409".
- Q1169059 iupacName "3".
- Q1169059 pubchem "54477".
- Q1169059 unii "223".
- Q1169059 type ChemicalSubstance.
- Q1169059 type Drug.
- Q1169059 type ChemicalObject.
- Q1169059 type Thing.
- Q1169059 type Q8386.
- Q1169059 comment "Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.".
- Q1169059 label "Remoxipride".
- Q1169059 depiction Remoxipride.svg.